All filters
Slidesets
Clinical case discussions | Howard Gurney, MBBS, FRACP
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017
Slidesets
Evaluation of a physiological based pharmacokinetic model to evaluate the influence of covariates on sunitinib exposure
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017
Slidesets
Optimal design – potential application in oncology drug development and clinical practice | Andrew Hooker, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017
Slidesets
Assessment of the release of daunorubicin from liposomes after administration of daunoXome® using population pharmacokinetics
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017
Slidesets
Model-based TDM for oncology drugs | Ron Keizer, PharmD, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017
Slidesets
Physiologically based PK model vs. Population PK approach during drug development | Italo Poggesi, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017
Slidesets
Opening Lecture: Inter- and intravariability in PK | Mark Ratain, MD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017
Slidesets
Trough dabrafenib plasma concentrations can predict occurrence of adverse effects requiring dose reduction in metastatic melanoma
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017
Slidesets
Clinical case discussions | Nielka van Erp, PharmD, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017
Slidesets
Modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017
Slidesets
PK and PKPD considerations for dose selection in the development of pembrolizumab | Dinesh de Alwis, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2017
Meeting
International Workshop on NASH Biomarkers 2017
5 May 2017 - 6 May 2017
美国
Slidesets
Innovation in histological assessment of NASH- Pierre Bedossa, MD, PhD
Presented at:
International Workshop on NASH Biomarkers 2017
Slidesets
EU perspective- Elmer Schabel, MD
Presented at:
International Workshop on NASH Biomarkers 2017
Slidesets
Session 2: Pathways to biomarker qualification and acceptance- Chris Leptak, MD, PhD
Presented at:
International Workshop on NASH Biomarkers 2017
Slidesets
Collaboration in action - Foundation for the National Institutes of Health- Roberto Calle, MD, FACE, FACP
Presented at:
International Workshop on NASH Biomarkers 2017
Slidesets
Collaboration in action - Innovative Medicines Initiative- Quentin Anstee, BSc, MB BS, PhD, MRCP(UK), FRCP
Presented at:
International Workshop on NASH Biomarkers 2017
Slidesets
Circulating nucleic acids and combination panels- Sven Francque, MD, PhD
Presented at:
International Workshop on NASH Biomarkers 2017
Slidesets
MRI; what can it deliver- Claude Sirlin, MD
Presented at:
International Workshop on NASH Biomarkers 2017
Slidesets
Role of genetic assessments- Quentin Anstee, BSc, MB BS, PhD, MRCP(UK), FRCP
Presented at:
International Workshop on NASH Biomarkers 2017